03:58 PM EDT, 03/11/2024 (MT Newswires) -- Indivior ( INDV ) said Monday that a study published in the Journal of Clinical Pharmacology showed Opvee 2.7 milligrams intranasal reversed opioid-induced respiratory depression faster than 4 milligrams dose of naloxone.

The head-to-head open label study met its primary goal with Opvee reversing respiratory depression produced by remifentanil within the first five minutes of administration whereas naloxone required 20 minutes to restore respiration to same levels, according to the company.

Indivior ( INDV ) said the study was part of Opvee development program and was reviewed by the US Food and Drug Administration, which approved the drug for emergency use of known or suspected opioid overdose in May.

Price: 22.11, Change: +0.81, Percent Change: +3.80